- Home
- CGAU vs VKTX Comparison
CGAU vs VKTX Comparison
Compare CGAU & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | VKTX |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CGAU | VKTX |
|---|---|---|
| Price | $17.36 | $29.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $16.67 | ★ $95.86 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.17 | N/A |
| Revenue Next Year | $13.62 | N/A |
| P/E Ratio | $11.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.35 | $22.96 |
| 52 Week High | $21.17 | $43.15 |
Technical Indicators
Market Signals| Indicator | CGAU | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 33.86 |
| Support Level | $16.43 | $23.08 |
| Resistance Level | $20.18 | $35.85 |
| Average True Range (ATR) | 0.76 | 1.56 |
| MACD | -0.25 | -0.53 |
| Stochastic Oscillator | 11.20 | 12.67 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.